Washington, D.C.—The New Jersey Senate has introduced a resolution calling on Congress and the President to “establish a safe daily level of consumption of cannabidiol through legislation,” according to a press release from the Natural Products Association (NPA).
New Jersey Senate Resolution No. 163 will be heard in the New Jersey State Senate Health, Human Services, and Senior Citizens Committee on Monday, November 18. It reads:
“Currently, the Food and Drug Administration (FDA) states that food additives or dietary supplements that contain cannabidiol are illegal under federal law. This is despite the fact that over 1,500 products that contain cannabidiol have arrived on the market without a clear approach from the FDA to regulate the products and ensure consumer safety. The lack of clear policy from the FDA and the patchwork regulation of substance by the states create a complex legal framework for companies that sell cannabidiol products for their operations. As a result, interstate commerce for national cannabidiol companies is difficult because banks, insurance companies, and merchant companies are uneasy about providing services to cannabidiol companies at the risk of involvement from the FDA. Therefore, the President and Congress of the United States should establish a safe daily level of consumption of cannabidiol because it would allow individuals to experience the medical benefits of cannabidiol products and generate economic activity by encouraging interstate commerce for cannabidiol companies.”
Related: NPA Poll: 51% of Americans Don’t Know CBD is Illegal
FDA Discusses Legality CBD at CRN Conference
NPA Granted Observer Status by Codex Alimentarius
Its bipartisan co-prime sponsors are Deputy Minority Leader Senator Bob Singer (NJ-30-R) and Chairman of the committee in question, Senator Joe Vitale (NJ-19-D).
NPA worked with lawmakers in NJ to pass the resolution, and is working with the U.S. Congress to pass legislation to set a safe level of consumption for CBD, the press release says. The U.S. Senate is currently considering legislation passed by the House that would appropriate $100,000 for FDA to perform a Health Hazard Evaluation and set a safe level of consumption for CBD.
Daniel Fabricant, Ph.D., President and CEO of NPA, said in the release: “The states are starting to take action to regulate the growing CBD marketplace but unless we get clear federal guidelines and safety standards, consumers are still going to be at risk. If Congress allows these products to go unregulated, the public is at risk for another vaping-like health crisis. Inaction from the FDA is bad for public health, bad for the benefits CBD offers and bad for the hemp industry’s growth and job-creating potential.”